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Background: Self-sampling for human papillomavirus (HPV) offered to women who do not participate in cervical cancer screening
is an increasingly popular method to increase screening coverage. The rationale behind self-sampling is that unscreened women
harbour a high proportion of undetected precancer lesions. Here, we compare the cervical intraepithelial neoplasia grade 2 or
worse (XCIN2) detection rate between non-attenders who participated in self-sampling and women attending routine screening.
Methods: A total of 23 632 women who were qualified as non-attenders in the Copenhagen Region were invited for HPV-based
self-sampling. Of these, 4824 women returned a self-sample, and HPV-positive women were referred for cytology and HPV co-
testing as follow-up. The entire cohort and a reference cohort (3347 routinely screened women) were followed for histopathology
confirmed XCIN2. Odds ratio (OR) and the relative positive predictive value of XCIN2 detection between the two populations
were estimated.
Results: Women participating in self-sampling had a higher XCIN2 detection than women undergoing routine cytology-based
screening (OR¼ 1.83, 95% CI: 1.21–2.77) and a similar detection as routinely screened women tested with cytology and HPV
testing (OR¼ 1.03, 95% CI: 0.75–1.40). The positive predictive value for XCIN2 was higher in screening non-attenders than in
routinely HPV- and cytology-screened screened women (36.5% vs 25.6%, respectively).
Conclusions: Self-sampling offered to non-attenders showed higher detection rates for XCIN2 than routine cytology-based
screening, and similar detection rates as HPV and cytology co-testing. This reinforces the importance of self-sampling for
screening non-attenders in organised cervical cancer screening.
A major challenge in preventing cervical cancer is the large
proportion of women who are screening non-attenders. In the
organised Danish cervical cancer screening programme, women
aged 23–49 years are invited every 3 years for screening, and
women 50–65 years of age are invited every 5 years. Approximately
75% of the target population is screened following these
recommendations, with minor regional and annual fluctuations
(Danish Quality Assurance Database for the Cervical Cancer
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Screening Program). Yet, 45% of new cancer cases are diagnosed
among non-attenders (Dugue et al, 2012).
Human papillomavirus (HPV)-based self-sampling has been
shown to increase screening participation in several studies
(Gok et al, 2010; Enerly et al, 2016; Sultana et al, 2016). In May
2014, we initiated ‘The Copenhagen Self-sampling Initiative’
(CSi) pilot to gain experience in how to best offer non-attenders
in the Capital Region of Denmark an HPV self-sampling test as
an alternative to the standard physician-taken cytology sample.
The CSi was designed as an implementation opt-in pilot study,
where approximately half of the women residing in the Capital
Region who had missed at minimum one screening round were
invited to order a self-sampling brush. As the pilot implementa-
tion was population based, the invited women had variable
screening history, ranging from those last screened 4 years
before the self-sampling invitation to those who had never been
screened. Overall, B20% of the 23 632 invited women
participated by returning a self-sampling brush. Of these, 40%
were long-term unscreened with no registered cytology in X10
years (Lam et al, 2017). By November 2016, an additional 18% of
the invited women passively or actively declined the self-
sampling invitation and instead went to their own general
practitioner (GP) for screening. In total, 38% of all invited
women were screened in an 18-month period after receiving the
self-sampling invitation.
A successful self-sampling strategy should not be less sensitive
for cervical intraepithelial neoplasia grade 2 or worse (XCIN2)
detection than routine screening. We investigated the detection
rate of XCIN2 among the screened women in a real-life self-
sampling setting, the CSi, and estimated the positive predictive
value of this procedure (with XCIN2 detection as a threshold).
Furthermore, we compared the observations to a population-based
routine screening cohort from the Horizon study (Preisler et al,
2013, 2016; Rebolj et al, 2013, 2014a, b, 2015a, 2016a, b; Bonde
et al, 2014; Ejegod et al, 2015). Samples from both cohorts were
tested in the same laboratory.
MATERIALS AND METHODS
The 23 632 screening non-attenders in the CSi implementation
study were invited to participate in screening via self-sampling
using an Evalyn brush (Rovers, Oss, The Netherlands). Non-
attenders were defined as women who had not been screened for at
least 4 (if aged 27–49 years) or 6 years (if aged 50–65 years).
Invitations for self-sampling were sent in batches of 1000 women
from May 2014 to April 2015; during this time, new routine
screening invitations may have been sent from the screening
programme. The women invited for self-sampling were sent a letter
with information on cervical cancer screening and the association
between HPV and cervical cancer; they could order a self-sampling
brush from our laboratory and return it using a prestamped
envelope. In total, 4865 returned their self-sampling test for HPV
testing on two or three different HPV assays (Figure 1). An
additional 4291 women were not screened via self-sampling, but
screened by a GP after receiving the self-sampling invitation letter.
Note that these numbers differ from those reported previously
(Lam et al, 2017), owing to a longer follow-up (November 2016
instead of December 2015). The HPV positivity was determined on
the CLART (Genomica, Madrid, Spain) and Onclarity (BD, Sparks,
MD, USA) assays for all samples. A subset of the first 1008 samples
was also analysed on Hybrid Capture 2 (HC2; Qiagen, Hilden,
Germany). Upon a positive HPV self-sample (i.e., if any of the
three HPV assays gave a positive test result), women were referred
to a GP-taken cytology follow-up sample. The follow-up samples
were co-tested with HPV and cytology. Based upon the outcome of
this follow-up test result, women were referred to re-testing or
gynaecology examinations. For the current study, the women
included in CSi were followed for 18 months (until November
2016) after the last invitations were sent.
For comparison, we have used data from the Horizon study that
was a population-based study of women routinely screened at their
GP. It included residual material from 5034 consecutive SurePath
cytology samples from women aged 16–89 years. The samples were
additionally tested for HPV using four different HPV assays (HC2,
cobas, CLART, and APTIMA), as described previously (Preisler
et al, 2013, 2016; Rebolj et al, 2013, 2014a, b, 2015a, 2016a, b;
Bonde et al, 2014; Ejegod et al, 2015). Horizon was nested into
routine practice. The women were therefore triaged according to
routine practice if they had cytology abnormal findings (defined as
atypical squamous cells of undetermined significance, XASCUS).
As an extra intervention in the Horizon study, cytology normal
and HPV-positive women had an active follow-up according to the
study protocol (Figure 2), where these women were invited for
repeat testing after 18 months.
Both studies were conducted at the Department of Pathology,
Copenhagen University Hospital (Supplementary Table 1). The
department was responsible for sending screening invitations and
testing of all cervical samples in the Copenhagen and Frederiksberg
municipalities when the Horizon study was undertaken between
June and August 2011 (this area covered B15% of all Danish
women eligible for cervical screening). From 2012 onwards, the
department was responsible for sending invitations and testing all
samples from the whole Capital Region (B33% of all eligible
women), where the CSi was implemented between May 2014 and
November 2015.
In order to ensure comparability of the cohorts, we excluded
women from the Horizon study who were outside the self-
sampling age range of 27–65 years (n¼ 1040), as well as women
with referral samples (which was women who had ASCUS or more
severe abnormality diagnosis registered in the previous 15 months,
or were HPV positive in the past 12 months, n¼ 647). Finally, the
two populations, Horizon (n¼ 3347) and CSi (n¼ 23 632), were
included in the analysis.
Data sources. Women’s screening status and history were
retrieved from the National Pathology Database (Patobank).
Patobank is a nationwide registry that covers all specimens from
all pathology departments in Denmark, and has been highly
complete since mid-2000s (Bjerregaard and Larsen, 2011).
Women’s screening status was determined by calculating the time
between the most recent test on record between 1 January 2000
and 6 May 2014, when we retrieved the list of eligible women to be
invited for self-sampling. For the Horizon study, this was between
1 January 2000 and the date the Horizon study sample was
collected in the routine laboratory.
If the referral, GP-taken, follow-up sample was cytology normal
and HPV positive, women were recommended for retesting after
12 months. The data for the CSi study were retrieved 18 months
after the last invitations were sent out, in November 2016. In the
Horizon study, cytology-normal and HPV-positive women were
invited by the laboratory to be retested after 18 months. The
histology follow-up took place until December 2013 that wasB30
months after study start.
Statistical analysis. Means and proportions were used to describe
the study populations. The outcome of interest was detection of
CIN2 or worse (XCIN2) vs normal biopsy/CIN1/no biopsy. All
abnormal histological findings in the CSi study were confirmed by
a chief physician reviewing the description, diagnosis code, and
electronic medical records. Odds ratios (ORs), their 95%
confidence intervals (CIs), and P-values of the association between
XCIN2 detection and explanatory variables were estimated in a
logistic regression model. The ORs were reported as crude and
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adjusted, where age, study and the women’s screening history were
taken into account. Cofactors were examined separately and as
potential confounders. Age and screening history were determined
to be a confounder of the association between the study
population, the exposure of interest, and XCIN2 detection, and
were therefore included in the adjusted model.
Four mutually exclusive population types were defined for the
analysis: one for the participants in the Horizon study, and three
for the women included in the CSi study: CSi-attenders (women
who returned their self-sampling test), GP-attenders (women who
had a physician-taken cytology sample), and non-responders
(invited women who neither responded to the CSi invitation nor
were screened by a GP).
Positive predictive value of XCIN2 detection was calculated as
the proportion of XCIN2 cases found among those who had an
adequate biopsy taken.
Screening history was categorised into two groups: intermit-
tently screened in case the women’s latest screening samples were
registered within 10 years before the study, and long-term
unscreened in case where the women’s last screening samples, if
any, were registered X10 years before the study.
All statistical analyses were performed using Stata 13.1.
(StataCorp, College Station, TX, USA).
Ethical approvals. Linkage of the data for both CSi and Horizon
was approved by the Danish Data Protection Agency under
notification number AHH-2015-084 I-Suite number: 04139, and
AHH-2015-084, I-Suite number: 04139, respectively. HPV testing
in the Horizon study did not require ethical approval, as it was
undertaken as a quality development study in concordance with
the Committee Act under The National Committee on Health
Research Ethics (2011 y14, part 3); the 18-month follow-up round
was approved by the Ethics Committee of the Danish Capital
Region (journal no. H-4-2012-120), and the women provided
informed consent. The CSi was a pilot implementation, mandated
by the Danish Health Authority and the Capital Region of
Denmark; ethical approval was therefore not required. Women
who ordered the self-sampling kit implicitly agreed to participate
in the implementation.
RESULTS
Of the 23 632 women invited to participate in self-sampling, 4865
(20.6%) returned a self-sampling test, typically within the first 6
months, 4291 (18.2%) had a cytology sample taken by a GP, and
14 476 (61.3%) had neither within the register-based follow-up
period (Figure 1). Of the 4865 CSi-attenders (women who returned
a self-sampling test), 737 (15.1%) were HPV positive, and referred
for an immediate routine cytology sample with HPV co-testing. In
total, 639 (86.8%) women had cytology and HPV follow-up,
among whom 98XCIN2 were detected. Six HPV-positive women
instead opted for a direct colposcopy, and three of these had
XCIN2. Two additional XCIN2 were detected among HPV-
negative CSI-attenders, despite not being recommended for
additional testing. In total, therefore, 103 (2.1%) XCIN2 were
detected among 4865 CSi-attenders (Table 1). Among the 4291
GP-attenders, 106 (2.5%) had a diagnosis of XCIN2, whereas 12
out of 14 476 (0.1%) women from the non-responders group had a
XCIN2 detected; the reason for these biopsies is unknown, but
Overall CIN2
detection rate:
(101+2)/4865 (2.1%)
Histology sample with
adequate material
N = 36
CIN2: 2
CSi invitations sent out
N = 23 632
CSi-attenders
4865*/23 632 (20.6%)
GP-attenders
N = 4291/23 632 (18.2%)
HPV+:
737/4865
(15.1%)
Adequate cytology follow-
up at GP
N = 639
ASCUS: 182/639 (28.5%)
Histology sample with
adequate material
N = 246
CIN2: 101 (2.1%)
Histology sample with
adequate material
N = 324
CIN2: 106/4291 (2.5%)
HPV-negative
N = 4124/4865
(84.9%) 
Histology sample:
N = 60
CIN2: 12/14 476
(0.1%)
Non-responders**
N = 14 476/23 632 (61.3%)
Figure 1. Flowchart of the CSi study design, follow-up triage, andXCIN2 detection rate. *Of all tested samples, 4 were invalid on all HPV assays,
773 samples had a positive test result on any of the three assays, and 246 of these had biopsies taken. Of the 4124 HPV-negative women, 36 had a
biopsy taken (for an unknown reason). Because of a hardware failure on the Onclarity assay, some women received their result based on CLART
and HC2 only. The samples were later re-tested on Onclarity, with 36 women having a positive test result. Owing to hospital practice, these
women did not receive a supplement result. The flowchart illustrates the follow-up process based on the result the women received, that is, the
result that influenced their clinical management. **Non-responders remained unscreened during the whole study period; the CIN2 or worse cases
detected might be symptom-related indications rather than screening. CIN¼ cervical intraepithelial neoplasia.
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may have been taken in response to symptoms – six of these lesions
were cervical cancer (Table 1).
In the Horizon study (Figure 2), 3347 screened women were
offered follow-up in case they had abnormal cytology or a positive
HPV test result on any of the four assays. The remaining women
were referred back to the routine screening programme. Overall,
336 histology diagnoses were retrieved with 86 XCIN2 (2.6%) in
the Horizon study. When excluding the XCIN2 found among
women in the per-protocol arm (repeat testing for women cytology
normal and HPV positive), and only including the XCIN2 found
in the cytology stand-alone protocol (which reflects the routine
screening programme), the XCIN2 detection was 58/3347 (1.7%).
The CSi-attenders were on average 7 years older than GP-
attenders in CSi and in the Horizon study (mean ages: 47.1 vs 40.3
vs 40.6 years, respectively). Almost all (94.2%) women in the
Horizon study were screened at least once in the preceding 10
years. This was the case for approximately two-thirds of CSi-
attenders (60.1%) and GP-attenders (69.2%), but for only 36.0% of
the CSi non-responders (who were also non-responders to routine
screening). Among the adequate biopsies, CSi-attenders and GP-
attenders had a higher detection of XCIN2 (positive predictive
value of an adequate biopsy: 36.5% and 32.7%, respectively) than
non-responders (20.0%) and women included in the Horizon study
(25.6%). Among all detected XCIN2, women were slightly more
likely to haveXCIN3 detected if they were CSI-attenders (78.6% of
allXCIN2 diagnoses wereXCIN3) or GP-attenders (78.3%) than
when they were routinely screened (72.1%, Horizon). In total, 18
women were diagnosed with cervical cancer in the CSi study, and
one in the Horizon study.
Women aged 430 years were significantly less likely to have a
XCIN2 diagnosis (Po0.01) compared with women aged 27–29
years, and this did not change after adjustment for population type
and screening history (Table 2). Without any adjustment,
intermittently screened women (women who were screened within
the past 10 years) appeared to have a higher risk of a XCIN2
diagnosis than long-term unscreened women (Po0.01). After
adjustment for age and population type, no significant difference
was observed between intermittently and long-term unscreened
women (P¼ 0.97). CSi-attenders (P¼ 0.18) and GP-attenders
(P¼ 0.78) appeared to have a similar (crude) risk of XCIN2
detection as women screened in the Horizon study that remained
virtually unchanged after adjustment for age and screening history
(P¼ 0.88 and P¼ 0.81, respectively). This was also the case if
screening history was re-defined as either the number of
unscreened years or dichotomised as unscreened for o6 and X6
years (P¼ 0.40 and P¼ 0.78, respectively; data not reported).
When we excluded the effect of HPV-based screening in the
Horizon study and compared the XCIN2 detection in CSi only
with cytology-based detection in Horizon (i.e., routine cytology-
based screening), CSi-attenders had a 1.83 times higher detection
of XCIN2 (adjusted OR¼ 1.83, 95% CI: 1.21–2.77, Po0.01). The
CSi non-responders had a significantly lower detection of XCIN2
than routinely screened women (Po0.01).
DISCUSSION
In our population-based study of screening non-attenders, HPV-
based self-sampling detected a similar proportion of XCIN2 as
routine screening with cytology and HPV-based co-testing, and a
higher proportion than stand-alone routine cytology-based screen-
ing. Furthermore, a slightly higher proportion of CIN3 and cervical
cancer was also observed among the CSi-attenders. The positive
predictive value for XCIN2 of a biopsy was slightly higher in CSi
Normal cytology and
HPV-negative
N = 2446/3347 (73.0%)
Horizon sample
collection
(N = 3347)*
Cytology and HPV
testing**
ASCUS
N = 162/3347
(4.8%) 
Adequate histology-
sample taken
N = 105
CIN2: 57 
Normal cytology and
HPV-positive=723/3347
(21.6%)
Adequate histology-
sample taken
N = 112
CIN2: 28
Overall CIN2-
detection rate:
(57+1+28)/3347
(2.6%) 
Adequate histology-
sample taken
N = 118
CIN2: 1
Figure 2. Flowchart of the Horizon study design, follow-up triage, and XCIN2 detection. *Of the 3347 screened women, 16 (0.48%) were
inadequate for cytology reading. One of the women had a histology sample registered with normal findings. This contributed to a total of 336
biopsies taken. **Women were followed-up according to routine practice based on the cytology result only. An active follow-up was performed on
women with cytology normal HPV-positive findings according to the study protocol that was repeat testing after 18 months. Women with normal
cytology and negative HPV test results were referred back to the routine screening programme; some of these had a histology sample taken
despite the recommendations. Women who were cytology negative and HPV positive were invited for repeated testing after 18 months. All HPV
test results reported here took into account the testing results on any of the four assays. CIN¼ cervical intraepithelial neoplasia.
BRITISH JOURNAL OF CANCER XCIN2 detection in screening non-attenders
4 www.bjcancer.com |DOI:10.1038/bjc.2017.371
compared with Horizon. This indicated that self-sampling was
effective and efficient in detecting high-grade CIN lesions whose
treatment might prevent future cases of cervical cancer.
From an implementation point of view, the CSi and the Horizon
studies illustrate the true impact of screening activities in a real-
world setup. The XCIN2 rate found in the CSi therefore
demonstrated the expected rates that would be found if self-
sampling would be added as an additional screening option for
women not attending routine screening.
Women who remained unscreened even after a self-sampling
invitation were highly unlikely to have a XCIN2 lesion detected
quite simply as they were not examined. Most of their CIN2 or
CIN3 lesions would go undetected until overtly symptomatic. In
our implementation study, 10% of all XCIN2 diagnoses in these
women were cancer, compared with p2% in women undergoing
routine or self-sampling screening. These women remain a
research priority to determine a better way of attracting them to
screening, although in younger birth cohorts this need will be
attenuated owing to HPV vaccination.
Few studies have compared the XCIN2 detection in screening
non-attenders who participate in self-sampling and in routinely
screened women. Bais et al (2007) compared 736 women
undergoing self-sampling (corresponding to our ‘CSi-attenders’
group) and an age-matched population-based cohort of 6208
routinely screened women (corresponding to the ‘Horizon’
population) as the reference group. This study found an overall
higher XCIN2 detection in the self-sampling group compared
with routinely screened women (OR¼ 2.59, 95% CI: 1.31–5.12).
A similarly higher detection of XCIN2 was found for self-
sampling participants compared with routine screening partici-
pants by Gok et al (2012), with a relative risk of 1.63 (95% CI:
1.4–1.9). Sultana et al (2016), on the other hand, reported in an
opt-out study that the detection of XCIN2 in 1649 women who
returned a self-sampling swab and in all screened women aged
30–69 years from the Australian state of Victoria were insignif-
icantly different from each other. These findings could be
explained by a shorter follow-up period in the self-sampling study
(6 months) that might lower the number of XCIN2 detected.
Our study had important strengths. Both the CSi and the
Horizon studies were population based and included representative
samples of routinely screened and routinely unscreened women.
With the use of the national Patobank for identifying outcomes in
both studies, our analysis had high data completeness in
identifying the detected XCIN2 cases. This was the case even if
the women moved outside of the laboratory’s catchment area,
thereby avoiding information bias. However, some limitations with
regard to the comparability of the CSi and the Horizon studies
need to be mentioned. Some of the CSi-attenders (N¼ 41) and GP-
attenders (N¼ 1029) in the CSi study had a follow-up time shorter
than 1.5 years because they were screened very late; these women
may have hadXCIN2 detected after the date of data retrieval. The
two populations differed somewhat in terms of their respective
screening catchment areas. The Horizon study covered the most
urbanised parts of the Capital Region, whereas the CSi covered the
whole Capital Region. Furthermore, the two studies varied in their
design, HPV testing methods and triage procedures
(Supplementary Table 1). Different HPV assays were used in the
studies and the Horizon study showed that HPV detection depends
on the assay (Rebolj et al, 2014b) that may affect the screening
follow-up referrals (Rebolj et al, 2016a). For this analysis, all
histological findings were retrieved, regardless of HPV results to
ensure that all outcomes were captured. The CSi study was
undertaken 3 years after the Horizon study. Changes in CIN
incidence may occur over time; however, with only a few years
Table 1. The characteristics of the two study populations
CSi (N¼23632) Horizon (N¼3347)
CSi-attenders
(n¼4865)
GP-attenders
(n¼4291)
Non-responders
(n¼14476)
GP-taken sample
(n¼3347)
Mean age (years; 95% CI) 47.1 (46.8–47.5) 40.3 (40.0–40.6) 47.6 (47.4–47.8) 40.6 (40.3–41.0)
Age group (years)
27–29 385 7.9% 588 13.7% 1318 9.1% 478 14.3%
30–39 1092 22.4% 1657 38.6% 2962 20.5% 1295 38.7%
40–49 1215 25.0% 1311 30.6% 3107 21.5% 897 26.8%
50–59 1275 26.2% 514 12.0% 4099 28.3% 462 13.8%
60–65 898 18.5% 221 5.1% 2990 20.7% 215 6.4%
Total 4865 100.0% 4291 100.0% 14476 100.0% 3347 100.0%
Screening historya
Long-term unscreened 1621 39.9% 927 30.8% 7540 64.0% 133 5.8%
Intermittently screened 2440 60.1% 2083 69.2% 4243 36.0% 2158 94.2%
Total 4061 100.0% 3010 100.0% 11783 100.0% 2291 100.0%
Histology (regardless of the HPV test result)
Normal 134 47.3% 188 57.8% 47 78.3% 206 56.3%
CIN1 45 15.9% 30 9.2% 1 1.7% 44 12.0%
CIN2 22 7.8% 23 7.1% 0 0.0% 24 6.6%
CIN3 76 26.9% 76 23.4% 6 10.0% 61 16.7%
Cervical cancer 5 1.8% 7 2.2% 6 10.0% 1 0.3%
Inadequate material 1 0.4% 1 0.3% 0 0.0% 30 8.2%
Total 283 100.0% 325 100.0% 60 100.0% 366 100.0%
XCIN2 detection (regardless of the HPV test result)
oCIN2 179 63.5% 218 67.3% 48 80.0% 250 74.4%
XCIN2 (positive predictive value) 103 36.5% 106 32.7% 12 20.0% 86 25.6%
Total 282 100.0% 324 100.0% 60 100.0% 336 100.0%
Positive predictive value of XCIN2 detection
compared with Horizon
Po0.01 P¼ 0.02 P¼0.93 Reference
Abbreviations: CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; GP¼general practitioner; HPV¼human papillomavirus; Intermittently screened¼ cytology sample registered
within the past 10 years (though not in the last screening round, see eligibility criteria); Long-term unscreened¼no cytology sample registered in the past 10 years.
aRestricted to women aged X34 years, N¼ 21 145 for both studies combined. These women have been recommended for screening for at least 10 years.
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between the studies, we consider it unlikely. No changes inXCIN2
detection over a 10-year period were previously found in the
catchment area of the Roskilde laboratory that is in close
geographical proximity to Copenhagen (Rebolj et al, 2015b).
Primary screening recommendations also remained unchanged
during those 3 years.
Based upon the resulting detection of XCIN2, self-sampling in
this setting appears to be more effective than the current cytology
routine screening, and would therefore lead to detection of an extra
number of high-grade lesions requiring treatment. However, to
finetune its implementation within an organised screening
programme, several issues still need to be addressed. These include
a definition of an optimal screening interval after a negative HPV
self-sample that will be investigated by register-based monitoring
of the screening and diagnostics activities of these women in the
forthcoming years via the Patobank. Furthermore, we speculate
that loss to follow-up could be reduced among self-sampling non-
attenders if, for example, a direct referral to colposcopy is
implemented for women with specific high-risk HPV genotypes
replacing part of the current uniform referral for cytology follow-
up. Finally, it is crucial for the integrity of an organised screening
programme to foresee the proportions of women who may switch
from GP-screening to self-sampling by skipping calls for screening
in order to obtain a non-responder status (Rozemeijer et al, 2015).
As organised cervical cancer screening depends on participation
within regular intervals, the latter could over time develop into a
challenge.
CONCLUSION
We observed higher detection rates of XCIN2 with HPV-based
self-sampling than in the routine cytology-based screening,
suggesting that self-sampling is a good screening alternative for
non-attenders. Furthermore, the proportion of high-grade CIN
lesions among all biopsies was high, suggesting that the chosen
referral approach was efficient.
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who were screened by a general practitioner; Intermittently screened¼women with a cytology sample registered within the past 10 years; Long-term unscreened¼women without a cytology
sample registered in the past 10 years; Non-responders¼women invited to CSi without a self-sampling or a GP cytology sample until end of follow-up; OR¼odds ratio.
aWhen using the per-protocol arm (cytology stand-alone screening) from the Horizon study as the reference group, the adjusted odds ratio for XCIN2 detection for CSi-attenders was
OR¼ 1.83 (95% CI: 1.21–2.77), Po0.01.
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